Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

InMed Pharmaceuticals (INM) Other Gross PP&E Adjustments (2021 - 2025)

InMed Pharmaceuticals' Other Gross PP&E Adjustments history spans 5 years, with the latest figure at $2.3 million for Q2 2025.

  • For Q2 2025, Other Gross PP&E Adjustments fell 10.55% year-over-year to $2.3 million; the TTM value through Jun 2025 reached $2.3 million, down 10.55%, while the annual FY2025 figure was $2.3 million, 10.55% down from the prior year.
  • Other Gross PP&E Adjustments reached $2.3 million in Q2 2025 per INM's latest filing, roughly flat from $2.3 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $2.6 million in Q1 2024 to a low of $40409.0 in Q4 2023.
  • Average Other Gross PP&E Adjustments over 5 years is $1.7 million, with a median of $1.6 million recorded in 2023.
  • Peak YoY movement for Other Gross PP&E Adjustments: tumbled 97.16% in 2023, then surged 5767.98% in 2024.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $1.4 million in 2021, then increased by 0.25% to $1.4 million in 2022, then crashed by 97.16% to $40409.0 in 2023, then soared by 5767.98% to $2.4 million in 2024, then fell by 1.71% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Other Gross PP&E Adjustments are $2.3 million (Q2 2025), $2.3 million (Q1 2025), and $2.4 million (Q4 2024).